Compare · EWTX vs JNJ
EWTX vs JNJ
Side-by-side comparison of Edgewise Therapeutics Inc. (EWTX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EWTX and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $556.77B, about 141.8x EWTX ($3.93B).
- Over the past year, EWTX is up 157.1% and JNJ is up 52.9% - EWTX leads by 104.2 points.
- EWTX has been more active in the news (13 items in the past 4 weeks vs 10 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 15 for EWTX).
- Company
- Edgewise Therapeutics Inc.
- Johnson & Johnson
- Price
- $36.48-0.79%
- $231.34+1.31%
- Market cap
- $3.93B
- $556.77B
- 1M return
- +11.22%
- +0.90%
- 1Y return
- +157.08%
- +52.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 13
- 10
- Recent ratings
- 15
- 25
Edgewise Therapeutics Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest EWTX
- SEC Form 4 filed by Director Brege Laura
- SEC Form 4 filed by Director Thompson Peter A.
- SEC Form 4 filed by Director Morris Arlene
- SEC Form 4 filed by Director Edris Badreddin
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Fox Jonathan C
- Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
- Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
- Edgewise Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Latest JNJ
- Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
- New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
- EVP, Chief TO and Risk Officer Wengel Kathryn E exercised 10,000 shares at a strike of $115.67 and sold $2,411,500 worth of shares (10,000 units at $241.15) (SEC Form 4)
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm